Key facts
- DeepUll’s last known valuation is $26.0M (Oct 2022).
- It has raised $91.3M; the latest was Later Stage VC ($50.0M) in Apr 2025.
- Notable investors include UI Investissement, Kurma Partners, CDTI Innvierte, Panakes Partners, Asabys Partners — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for DeepUll
- ·The full record, as it builds
Funding rounds
No funding rounds for DeepUll are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About DeepUll
Operator of a biotechnology company intended to offer an early diagnosis of sepsis and therapeutic recommendations. The company uses artificial intelligence to identify the causative infective agent and provide phenotypic antimicrobial susceptibility results, reducing the unnecessary use of antimicrobials and developing a new diagnostic system that will detect pathogens and antibiotic resistance, without a prior cultivation stage, enabling patients to get treated in the early stages of the disease.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2019
- Employees
- 41
- Website
- deepull.com/
- Ownership
- Privately Held (backing)
DeepUll doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in DeepUll shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on DeepUll in its N-PORT filings yet. We sweep new filings monthly.